Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
about
Update on Advances in Research on Idiosyncratic Drug-Induced Liver InjuryRisk factors associated with adverse reactions to antituberculosis drugsA microbiological revolution meets an ancient disease: improving the management of tuberculosis with genomicsIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisAnti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patientsIncidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort studyTranslating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyThe incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1Mechanism of isoniazidāinduced hepatotoxicity: then and nowHuman leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.Data-driven methods to discover molecular determinants of serious adverse drug events.Antitubercular therapy in patients with cirrhosis: challenges and optionsDrug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or NecrosisRifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature reviewEvaluation of anti-tuberculosis induced adverse reactions in hospitalized patients.A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersPharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients.Pharmacogenomics of antimicrobial agents.Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan populationTuberculosis, lung infections, interstitial lung disease, and journalology in AJRCCM 2002.Risk factors for idiosyncratic drug-induced liver injury.Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients.Targeting the issues in chronic obstructive lung disease.Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.Pharmacogenetics of isoniazid-induced hepatotoxicity.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injuryViral hepatitis prevalence in patients with active and latent tuberculosis.NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.Role of pharmacogenomics in the treatment of tuberculosis: a reviewAntituberculosis drugs and hepatotoxicity.Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.
P2860
Q26779078-E4D27A23-0BE5-478A-A2CD-F638CFB6EC1EQ26863380-35DAC6C9-FD68-43FE-8368-80B13A91B516Q26999868-6E962DEB-E120-468D-9BEB-26A07BB18972Q28207601-0A79822D-2A1C-442A-A745-ABF2BA972802Q28472348-A9656C4F-89C7-4BC1-9163-4A65347EED52Q28478173-F9C4FC78-708F-428D-8489-832900F191B0Q28478443-4C89AF41-145E-437F-A818-2E7A3BE4C1BEQ28488142-842CB80A-F5C6-4EDD-849D-8B932EF3DB35Q28539060-16D33FEB-18AB-4E3A-ADC0-DC48AE7FC73DQ29248263-2AC5F3C3-943A-4165-9E0D-58A7272F9739Q30238992-9B897AD7-07F9-4D55-B15A-9EBC501652B2Q33403734-0E6DD712-F5E1-4C23-9E27-8B2A50695689Q33626827-371AB0CC-88B1-4403-8162-7004AAB72BA6Q33755165-763379D9-28D5-4FA4-8514-3B5BAA02923AQ34116293-799F2841-3A8B-4137-BDCE-71CB38FD08AEQ34145133-8450876D-89F4-48E3-A078-AC26A0BE6555Q34208933-DB7B6EA9-8774-45F2-B388-2FA64A355C5DQ34316771-C3A03026-9EE4-455E-9BBF-E7D3D625F855Q34342305-B78CC363-2AE4-4A5B-B535-F58404534842Q34606196-D7C0E040-D817-40D2-A5B9-621E69381269Q34660150-8FB81619-C13C-445E-9151-BBD9B3FAC06CQ34977413-604B1B17-2677-44E3-9252-570AE1732413Q34986858-A16BAE34-C7EE-4157-BED0-5B21A6659954Q35055456-B0ABDD4F-CF2C-4DD0-9D20-310D46A53CE8Q35168108-4F9EE05A-D766-41F4-BFE2-082B5A0B4CCDQ35534713-F65092AA-E31C-4FDB-ABA2-E36B05C84CE4Q35581145-74A034A0-18C6-435D-91AA-D0E78E344941Q35656015-FEB020B3-2CAD-4654-A744-01D42FE3987EQ35669887-3D8A3E06-83CF-4E62-9717-F130A4FC1440Q35786010-058491F9-12E3-46D9-A22B-F79CD1AF3563Q35911420-C7D8C32A-79EA-4A19-883C-A8373EDC05D3Q35925537-A50FF7A0-6D8B-46ED-B922-DEFB354C9FB8Q35934555-E35D4243-7D77-4709-9688-85D20539C669Q36058879-C267C88F-5089-47C3-BDC4-871FF5CA747BQ36190248-72BF9935-01F4-410A-9EEE-531712617904Q36408248-8FD694DA-D8F4-4AC8-8479-4DF28187B329Q36412863-D4ACB972-9B62-4E06-880F-DE72FB9E70D8Q36441540-7BBE67C0-C583-4369-94CD-CC122036E6D8Q36628708-08A21817-9DCF-47D6-AC8E-F79E5499DD62Q36725202-1833BEC5-DDEA-4323-BF86-48A196A061A1
P2860
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
description
2002 nĆ® lÅ«n-bĆ»n
@nan
2002幓ć®č«ę
@ja
2002幓å¦ęÆęē«
@wuu
2002幓å¦ęÆęē«
@zh
2002幓å¦ęÆęē«
@zh-cn
2002幓å¦ęÆęē«
@zh-hans
2002幓å¦ęÆęē«
@zh-my
2002幓å¦ęÆęē«
@zh-sg
2002幓åøč”ęē«
@yue
2002幓åøč”ęē«
@zh-hant
name
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@en
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@nl
type
label
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@en
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@nl
prefLabel
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@en
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@nl
P2093
P2860
P356
P1476
Evaluation of clinical and imm ...... ng antituberculosis treatment.
@en
P2093
Arumugam Balamurugan
Narinder K Mehra
Pradip Kumar Saha
Ravindra M Pandey
Surendra K Sharma
P2860
P304
P356
10.1164/RCCM.2108091
P407
P577
2002-10-01T00:00:00Z